Transforming Large B-Cell Lymphoma (LBCL): CAR T and Novel Agents

Experts explore the transformative impact of CAR T-cell therapy on lymphoma treatment, covering mechanisms of action, first-line applications, and ongoing challenges.

EP. 11: ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL

December 12th 2023

A dive into the latest results from the ZUMA-1 study, evaluating axicabtagene ciloleucel (axi-cel) in relapsed/refractory LBCL.

EP. 12: Lisocabtagene Maraleucel: A Review of TRANSCEND NHL 001 in R/R LBCL

December 19th 2023

Gain insights into treatment outcomes of CAR T, highlighting lisocabtagene maraleucel and the TRANSCEND NHL 001 study for R/R LBCL.

EP. 13: Observations in Progression Post-CAR T for Lymphoma

December 19th 2023

A comprehensive overview of clinical and patient factors that impact disease progression beyond CAR T-cell therapy in lymphoma.

EP. 14: Emerging Bispecifics in the Treatment Paradigm for R/R LBCL

December 26th 2023

Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).

EP. 15: Future Perspectives in Large B-Cell Lymphoma

December 26th 2023

Fred Locke, MD shares his perspective on the future treatment paradigm in large B-cell lymphoma, emphasizing CAR-T cells, allogeneic strategies, bispecifics, toxicity management, and treatment sequencing.